Cardioprotective Properties of Omentin-1 in Type 2 Diabetes: Evidence from Clinical and In Vitro Studies

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Greulich, Sabrina ^a   Chen, Weena J Y ^b   Maxhera, Bujar ^c   Rijzewijk, Luuk J ^b   van der Meer, Rutger W ^d   Jonker, Jacqueline T ^d   Mueller, Heidi ^a   de Wiza, Daniella Herzfeld ^a   Floerke, Ralf Ruediger ^a   Smiris, Konstantinos ^c   Lamb, Hildo J ^d   de Roos, Albert ^d   Bax, Jeroen J ^d   Romijn, Johannes A ^e   Smit, Jan W A ^d,g   Akhyari, Payam ^c   Lichtenberg, Artur ^c   Eckel, Juergen ^a   Diamant, Michaela ^b   Ouwens, D Margriet ^a,f  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Orthopedic Surgery   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; GLIMEPIRIDE; METFORMIN; OMENTIN 1; PIOGLITAZONE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; AGED; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIASTOLE; DRUG DOSE TITRATION; HEART CONTRACTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ADIPOSE TISSUE; AGED; ANIMALS; CASE-CONTROL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; INSULIN; LECTINS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MYOCYTES, CARDIAC; RATS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84875535073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059697     Document Type: Article

References (39)

1. Iozzo P, (2010) Metabolic toxicity of the heart: insights from molecular imaging. Nutr Metab Cardiovasc Dis 20: 147-156.
2. Ouwens DM, Diamant M, (2007) Myocardial insulin action and the contribution of insulin resistance to the pathogenesis of diabetic cardiomyopathy. Arch Physiol Biochem 113: 76-86.
3. Greulich S, Herzfeld de Wiza D, Preilowski S, Ding Z, Mueller H, et al. (2011) Secretory products of guinea pig epicardial fat induce insulin resistance and impair primary adult rat cardiomyocyte function. J Cell Mol Med 15: 2399-2410.
4. Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, et al. (2009) Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 105: 326-334.
5. Ouwens DM, Sell H, Greulich S, Eckel J, (2010) The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 14: 2223-2234.
6. Greulich S, Maxhera B, Vandenplas G, Herzfeld de WD, Smiris K, et al. (2012) Secretory Products from Epicardial Adipose Tissue of Patients with Type 2 Diabetes Induce Cardiomyocyte Dysfunction. Circulation in press.
7. Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, et al. (2011) New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 12: 60.
8. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, et al. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56: 1655-1661.
9. Liu R, Wang X, Bu P, (2011) Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 93: 21-25.
10. Pan HY, Guo L, Li Q, (2010) Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 88: 29-33.
11. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, et al. (2008) Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 57: 801-808.
12. Yan P, Liu D, Long M, Ren Y, Pang J, et al. (2011) Changes of Serum Omentin Levels and Relationship between Omentin and Adiponectin Concentrations in Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes 119: 257-263.
13. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, et al. (2010) Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 7: 27.
14. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, et al. (2011) Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity (Silver Spring) 19: 1552-1559.
15. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, et al. (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290: E1253-E1261.
16. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H, (2012) Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 686: 116-123.
17. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, et al. (2008) Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond) 32: 810-815.
18. Iacobellis G, Willens HJ, (2009) Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 22: 1311-1319.
19. Iozzo P, (2011) Myocardial, perivascular, and epicardial fat. Diabetes Care 34Suppl 2: S371-S379.
20. Smith U (2001) Pioglitazone: mechanism of action. Int J Clin Pract Suppl 13-18.
21. van der Meer RW, Diamant M, Westenberg JJ, Doornbos J, Bax JJ, et al. (2007) Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson 9: 645-651.
22. van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, et al. (2009) Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 119: 2069-2077.
23. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, et al. (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54: 1524-1532.
24. Jonker JT, Lamb HJ, van der Meer RW, Rijzewijk LJ, Menting LJ, et al. (2010) Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95: 456-460.
25. Defronzo RA, Tobin JD, Andres R, (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223.
26. Rijzewijk LJ, van der Meer RW, Lubberink M, Lamb HJ, Romijn JA, et al. (2010) Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. Diabetes 59: 2747-2754.
27. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, et al. (2007) Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50: 1038-1047.
28. Thalmann S, Juge-Aubry CE, Meier CA, (2008) Explant cultures of white adipose tissue. Methods Mol Biol 456: 195-199.
29. Greulich S, Herzfeld de Wiza D, Preilowski S, Ding Z, Mueller H, et al. (2011) Secretory products of guinea pig epicardial fat induce insulin resistance and impair primary adult rat cardiomyocyte function. J Cell Mol Med 15: 2399-2410.
30. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, et al. (2010) Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 59: 3023-3031.
31. Yan P, Li L, Yang M, Liu D, Liu H, et al. (2011) Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 92: 368-374.
32. Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, et al. (2011) Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 10: 67.
33. Duan XY, Xie PL, Ma YL, Tang SY, (2011) Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 41: 1223-1231.
34. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y, (2010) Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 393: 668-672.
35. Akbarzadeh S, Nabipour I, Assadi M, Movahed A, Jafari SM, et al. (2012) The normoglycemic first-degree relatives of patients with type 2 diabetes mellitus have low circulating omentin-1 and adiponectin levels. Cytokine 58: 295-299.
36. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, et al. (2013) Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Regul Pept.
37. El-Mesallamy HO, El-Derany MO, Hamdy NM, (2011) Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 28: 1194-1200.
38. Fioravanti A, Simonini G, Cantarini L, Generoso M, Galeazzi M, et al. (2011) Circulating levels of the adipocytokines vaspin and omentin in patients with Kawasaki disease. Rheumatol Int.
39. Ouchi N, Parker JL, Lugus JJ, Walsh K, (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11: 85-97.